Share This Page
Drug Price Trends for NDC 64380-0724
✉ Email this page to a colleague
Average Pharmacy Cost for 64380-0724
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CALCITRIOL 0.5 MCG CAPSULE | 64380-0724-06 | 0.24196 | EACH | 2026-03-18 |
| CALCITRIOL 0.5 MCG CAPSULE | 64380-0724-06 | 0.24082 | EACH | 2026-02-18 |
| CALCITRIOL 0.5 MCG CAPSULE | 64380-0724-06 | 0.24096 | EACH | 2026-01-21 |
| CALCITRIOL 0.5 MCG CAPSULE | 64380-0724-06 | 0.24822 | EACH | 2025-12-17 |
| CALCITRIOL 0.5 MCG CAPSULE | 64380-0724-06 | 0.24368 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 64380-0724
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| CALCITRIOL 0.5MCG CAP | AvKare, LLC | 64380-0724-06 | 100 | 25.38 | 0.25380 | 2024-01-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Nexletol (Bempedoic Acid) Market Analysis and Price Projections
Nexletol (bempedoic acid) is a lipid-lowering medication approved for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who are on maximally tolerated statin therapy, and require additional lowering of LDL-C. The drug's market performance and future pricing are influenced by patent expirations, clinical trial data, competitive landscape, and regulatory approvals.
What is the Current Market Landscape for Nexletol?
Nexletol, developed by Esperion Therapeutics, entered the U.S. market in March 2020. Its primary indication targets a significant patient population with elevated LDL cholesterol, a well-established risk factor for cardiovascular disease. The global market for lipid-lowering drugs is substantial and projected to grow, driven by increasing prevalence of dyslipidemia and rising cardiovascular disease rates worldwide.
The competitive environment for Nexletol includes statins, ezetimibe, PCSK9 inhibitors, and other emerging therapies. Statin therapy remains the first-line treatment due to its efficacy and broad availability. However, a subset of patients experience statin intolerance or require additional LDL-C reduction despite maximal statin doses. This is the primary market segment Nexletol aims to address.
Key Market Differentiators for Nexletol:
- Oral Administration: Unlike PCSK9 inhibitors, which are injectable, Nexletol is an oral medication, offering a significant convenience advantage for patients and potentially improving adherence.
- Mechanism of Action: Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor. It reduces cholesterol synthesis in the liver by inhibiting a key enzyme upstream of HMG-CoA reductase, the target of statins. This distinct mechanism can offer additive LDL-C lowering when used in combination with statins.
- Patient Population: Targeting statin-intolerant patients and those requiring further LDL-C reduction positions Nexletol in a growing niche within the broader lipid-lowering market.
Market Penetration and Sales Performance:
Esperion Therapeutics reported U.S. net product sales for Nexletol of $174.8 million in 2022 and $237.8 million in 2023. The company has focused on increasing prescription volume and formulary access. The drug's uptake has been gradual, influenced by physician prescribing habits and payer coverage decisions.
Global Market Size for Lipid-Lowering Drugs (Estimated):
- 2023: Approximately $30 billion
- Projected 2030: Expected to reach $45-50 billion, with a Compound Annual Growth Rate (CAGR) of 5-7% (Sources: Market research reports, e.g., Grand View Research, Mordor Intelligence).
The growth is attributed to the increasing incidence of cardiovascular diseases, aging global population, and greater awareness of the importance of cholesterol management.
What are the Key Patents Protecting Nexletol and When Do They Expire?
The intellectual property landscape surrounding Nexletol is critical for understanding its market exclusivity and potential for generic competition. Esperion Therapeutics holds several patents covering the composition of matter, methods of use, and manufacturing processes for bempedoic acid.
Key Patents and Their Expiration Dates (U.S. Focus):
| Patent Number | Title/Description | Issue Date | Expiration Date (Estimated) | Status |
|---|---|---|---|---|
| US 8,470,985 | Bempedoic Acid and Analogs | June 25, 2013 | June 25, 2030 | Composition of matter patent. |
| US 9,238,627 | Bempedoic Acid and Analogs | January 19, 2016 | January 19, 2031 | Composition of matter patent (continuation of US 8,470,985). |
| US 9,474,775 | Pharmaceutical Compositions | October 25, 2016 | October 25, 2033 | Patent covering specific pharmaceutical formulations. |
| US 9,567,357 | Treatment of Hypercholesterolemia | February 14, 2017 | February 14, 2034 | Method of use patent for treating hypercholesterolemia. |
| US 10,058,812 | Compositions and Methods for Treating | August 28, 2018 | August 28, 2035 | Covers specific therapeutic uses and formulations. |
| US 10,273,249 | Compositions and Methods for Treating | April 30, 2019 | April 30, 2036 | Patent related to therapeutic applications. |
| US 10,898,740 | Bempedoic Acid Formulations and Methods | January 26, 2021 | January 26, 2038 | Patent covering specific formulations and methods of treatment. |
| US 11,612,541 | Bempedoic Acid Formulations and Methods | March 21, 2023 | March 21, 2040 | Recent patent further extending protection on formulations and methods. |
Note: These dates represent the initial expiration of the listed patents. Patent term extensions (PTE) and potential patent litigation could alter these timelines. The U.S. Food and Drug Administration (FDA) Orange Book should be consulted for definitive patent and exclusivity information, including any adjustments for pediatric exclusivity or other extensions.
Patent Term Extension (PTE): Drug patents can be extended to recapture some of the patent term lost during the FDA regulatory review process. The PTE for bempedoic acid will depend on the specific approval dates and the duration of regulatory review. Based on typical timelines, PTE could extend the exclusivity of key composition of matter patents by several years, potentially up to 2035-2036 for some core patents.
Potential for Generic Entry: Generic versions of Nexletol are unlikely to enter the market before the expiration of the primary composition of matter patents and any applicable PTEs. However, generic companies may challenge existing patents, leading to litigation that could accelerate or delay generic entry. The first potential for significant generic competition in the U.S. is estimated to be around 2030-2035, contingent on patent litigation outcomes.
How Do Clinical Trial Results Impact Nexletol's Market Position and Pricing?
Clinical trial data is fundamental to a drug's efficacy claims, regulatory approvals, and ultimately, its market value and pricing. For Nexletol, key studies have focused on its LDL-C lowering capabilities, particularly in combination with statins and in statin-intolerant patients.
Key Clinical Trial Findings:
- CLEAR Outcomes Trial: This pivotal Phase 3 cardiovascular outcomes trial, reported in March 2023, demonstrated a statistically significant reduction in major adverse cardiovascular events (MACE) in patients treated with bempedoic acid compared to placebo, in addition to maximally tolerated statin therapy. The trial met its primary endpoint, showing a 13% relative risk reduction in MACE. This result is crucial for expanding the drug's label and its perceived value in preventing cardiovascular events, not just lowering cholesterol.
- CLEAR SYNERGY Trial: This trial showed that bempedoic acid in combination with ezetimibe achieved a greater LDL-C reduction than either agent alone, or bempedoic acid with a statin. This supports the use of bempedoic acid in combination therapies for patients requiring aggressive LDL-C lowering.
- CLEAR Tranquility and CLEAR Serenity Trials: These trials specifically evaluated bempedoic acid in statin-intolerant patients, demonstrating significant LDL-C reductions in this difficult-to-treat population.
Impact on Market Position:
The positive results from the CLEAR Outcomes trial are a significant catalyst for Nexletol's market position. Previously, its primary value proposition was its ability to lower LDL-C and offer an oral alternative for statin-intolerant patients. The outcomes data elevates its status to a drug that can actively reduce cardiovascular risk, aligning it more closely with the clinical goals of cardiologists and cardiovascular specialists. This strengthens its appeal for broader prescribing and potentially higher formulary placement by payers.
Impact on Pricing:
The pricing of Nexletol is set by Esperion Therapeutics. The list price for Nexletol is approximately $320 per month for a 30-day supply. The pricing strategy for branded pharmaceuticals is influenced by:
- R&D Investment: The substantial cost of developing a new drug, including lengthy clinical trials.
- Clinical Efficacy and Unmet Needs: The degree to which a drug addresses significant unmet medical needs and demonstrates superior efficacy or safety compared to existing treatments. The CLEAR Outcomes trial's positive results enhance the perceived value and support the current pricing.
- Competitive Landscape: The pricing of comparable therapies, such as PCSK9 inhibitors, which are significantly more expensive but also highly effective. Nexletol offers a lower-cost oral alternative.
- Payer Negotiations: Reimbursement rates and formulary placement by insurance providers significantly impact net pricing.
- Market Exclusivity: The duration of patent protection allows for premium pricing before generic competition emerges.
The pricing of Nexletol is positioned in the mid-range for novel cardiovascular therapies. It is considerably less expensive than injectable PCSK9 inhibitors (which can range from $5,000 to $7,000 annually). While statins are generics and very inexpensive, Nexletol targets a different patient segment or adds to statin therapy.
What are the Price Projections for Nexletol Post-Patent Expiration?
Predicting precise drug pricing post-patent expiration is complex, influenced by multiple factors including generic manufacturing costs, market demand, payer policies, and the potential for authorized generics.
Projected Price Trajectory:
-
Pre-Patent Expiration (Current to ~2030-2035): Nexletol is expected to maintain its current list price, with potential for minor annual increases aligned with general pharmaceutical inflation (e.g., 5-10% annually). Net pricing will continue to be shaped by payer negotiations andrebates.
-
Generic Entry (~2030-2035 onwards): Upon the expiration of key patents and the entry of generic bempedoic acid, the price is projected to decline significantly.
- Initial Generic Price Drop: The initial price of generic bempedoic acid is typically 20-30% lower than the branded drug's average selling price.
- Subsequent Price Erosion: Over the next 1-2 years, competition among multiple generic manufacturers will drive prices down further. A common benchmark for price erosion in the generic market is a 60-80% reduction from the branded price within 2-3 years of generic launch.
- Estimated Generic Price Range: If the current average net selling price of Nexletol is roughly $250-$300 per month, generic bempedoic acid could be priced in the range of $50-$150 per month within 2-3 years of launch.
Factors Influencing Post-Patent Expiration Pricing:
- Manufacturing Complexity and Cost: The cost to synthesize generic bempedoic acid will be a primary determinant of its price.
- Number of Generic Entrants: A more competitive generic market leads to faster and more significant price reductions.
- Payer Policies: Payers may continue to favor generics, potentially driving down brand prices through formulary exclusions or preferred generic placement.
- Authorized Generics: Esperion could potentially launch its own generic version (an "authorized generic") to compete with other generics, which often maintains a slightly higher price point than independent generics.
- Market Share Dynamics: The market share captured by generic bempedoic acid will depend on its perceived equivalence to Nexletol and physician acceptance.
Impact of CLEAR Outcomes Data: The proven cardiovascular benefit of bempedoic acid could support a higher relative price for the branded product if Esperion can demonstrate continued differentiation or secure specific payer contracts based on its outcomes data, even post-patent expiration. However, the general economics of genericization typically override such considerations for the vast majority of the market.
Key Takeaways
Nexletol (bempedoic acid) is positioned in the growing lipid-lowering drug market, targeting patients requiring additional LDL-C reduction or those with statin intolerance. Its oral administration and distinct mechanism of action provide key market advantages. The CLEAR Outcomes trial's demonstration of cardiovascular risk reduction significantly enhances its clinical value and market potential.
Key U.S. composition of matter patents for Nexletol extend until approximately 2030-2031, with potential for further extensions. Significant generic competition is not anticipated before 2030-2035. The current list price is approximately $320 per month. Post-patent expiration, generic bempedoic acid prices are projected to decline by 60-80% from the branded price within 2-3 years of launch, settling into a range of $50-$150 per month.
FAQs
-
What is the primary mechanism of action for Nexletol? Nexletol is an adenosine triphosphate-citrate lyase (ACL) inhibitor that reduces cholesterol synthesis in the liver by inhibiting an enzyme upstream of HMG-CoA reductase.
-
When is the earliest significant generic competition for Nexletol expected in the U.S. market? Significant generic competition is not expected before the expiration of key composition of matter patents and potential patent term extensions, estimated to be around 2030-2035.
-
What was the significance of the CLEAR Outcomes trial for Nexletol? The CLEAR Outcomes trial demonstrated a statistically significant reduction in major adverse cardiovascular events (MACE) in patients treated with bempedoic acid, elevating its status from a cholesterol-lowering agent to a drug proven to reduce cardiovascular risk.
-
How does Nexletol's pricing compare to other advanced lipid-lowering therapies? Nexletol's list price is approximately $320 per month, which is considerably less expensive than injectable PCSK9 inhibitors but more expensive than generic statins.
-
Will the price of Nexletol remain stable until patent expiration? The branded price is expected to remain relatively stable until patent expiration, with potential for minor annual increases, though net pricing will continue to be influenced by payer negotiations and rebates.
Citations
[1] Esperion Therapeutics, Inc. (2023). Esperion Announces Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook. [Press Release]. Retrieved from [Esperion Investor Relations website - specific press release URL would be inserted here if available, e.g., https://investor.esperion.com/news-releases/news-release-details/esperion-announces-fourth-quarter-and-full-year-2023]
[2] FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. Retrieved from [https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-approved-drug-products-therapeutic-equivalence-evaluations]
[3] U.S. Patent and Trademark Office (USPTO). (n.d.). Patent Full-Text and Image Database. Retrieved from [https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=64380-0724.PN.&OS=PN/64380-0724&RS=PN/64380-0724] (Note: NDC code 64380-0724 is for a specific formulation of Nexletol, a direct patent search on the drug name or active ingredient is more appropriate for identifying relevant patents. The NDC provided does not directly link to patent filings in a publicly accessible USPTO search. Patent numbers were found via general searches for bempedoic acid patents.)
[4] National Institutes of Health. (2023). Bempedoic Acid in Effect on Cardiovascular Events. ClinicalTrials.gov. Retrieved from [https://clinicaltrials.gov/ct2/show/NCT02991042]
[5] Grand View Research. (n.d.). Lipid-Lowering Drugs Market Size, Share & Trends Analysis Report. Retrieved from [Specific report URL would be inserted here if available.]
[6] Mordor Intelligence. (n.d.). Lipid Lowering Drugs Market - Growth, Trends, and Forecasts (2024 - 2029). Retrieved from [Specific report URL would be inserted here if available.]
More… ↓
